|
1) Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-8
|
|
|
|
2) Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771-80
|
|
|
|
|
|
3) Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004; 19: 179-84
|
|
|
|
|
|
4) Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349: 446-56
|
|
|
|
|
|
5) Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16: 1115-25
|
|
|
|
|
|
6) Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006; 70: 1858-65
|
|
|
|
|
|
7) Gal-Moscovici A, Sprague SM. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res. 2007; 22(Suppl 2): V91-4
|
|
|
|
|
|
8) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: S1-201
|
|
|
|
|
|
9) Kristal-Boneh E, Froom P, Harari G, et al. Association of calcitriol and blood pressure in normotensive men. Hypertension. 1997; 30: 1289-94
|
|
|
|
|
|
10) Zittermann A, Schleithoff SS, Tenderich G, et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure？ J Am Coll Cardiol. 2003; 41: 105-12
|
|
|
|
|
|
11) Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72: 1004-13
|
|
|
|
|
|
12) Cardus A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res. 2007; 22: 860-6
|
|
|
|
|
|
13) Rajasree S, Umashankar PR, Lal AV, et al. 1, 25-dihydroxyvitamin D3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. Life Sci. 2002; 70: 1777-88
|
|
|
|
|
|
14) Cardus A, Parisi E, Gallego C, et al. 1, 25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 2006; 69: 1377-84
|
|
|
|
|
|
15) Carthy EP, Yamashita W, Hsu A, et al. 1, 25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension. 1989; 13: 954-9
|
|
|
|
|
|
16) Hirata M, Katsumata K, Endo K, et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1, 25(OH)2 vitamin D3. Nephrol Dial Transplant. 2003; 18: 1770-6
|
|
|
|
|
|
17) Mizobuchi M, Finch JL, Martin DR, et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007; 72: 709-15
|
|
|
|
|
|
18) Wu-Wong JR, Noonan W, Ma J, et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther. 2006; 318: 90-8
|
|
|
|
|
|
19) Noonan W, Koch K, Nakane M, et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant. 2008; 23: 3824-30.
|
|
|
|
|
|
20) Nibbelink KA, Tishkoff DX, Hershey SD, et al. 1, 25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol. 2007; 103: 533-7
|
|
|
|
|
|
21) Tishkoff DX, Nibbelink KA, Holmberg KH, et al. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology. 2008; 149: 558-64
|
|
|
|
|
|
22) Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005; 288: E125-32
|
|
|
|
|
|
23) Yuan W, Pan W, Kong J, et al. 1, 25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007; 282: 29821-30
|
|
|
|
|
|
24) Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007; 104: 16810-5
|
|
|
|
|
|
25) Kim HW, Park CW, Shin YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract. 2006; 102: c21-9
|
|
|
|
|
|
26) Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1999; 33: 73-81
|
|
|
|
|
|
27) Doherty TM, Tang W, Dascalos S, et al. Ethnic origin and serum levels of 1alpha, 25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation. 1997; 96: 1477-81
|
|
|
|
|
|
28) Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997; 96: 1755-60
|
|
|
|
|
|
29) Goldsmith DJ, Covic A, Sambrook PA. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron. 1997; 77: 37-43
|
|
|
|
|
|
30) London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 1943-51
|
|
|
|
|
|
31) Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008; 168: 397-403
|
|
|
|
|
|
32) Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008; 19: 1613-9
|
|
|
|
|
|
33) Mathew S, Lund RJ, Chaudhary LR, et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008; 19: 1509-19
|
|
|
|
|